Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics

por Larson, Kajal B, King, Jennifer R, Acosta, Edward P
Publicado 2013

2549. Pharmacometric Analyses to Support Sulbactam-Durlobactam (SUL-DUR) Dosing Regimens in Patients with Altered Renal Function

por Larson, Kajal, Bhavnani, Sujata M, Hammel, Jeffrey P, Cammarata, Anthony P, O’Donnell, John, Rubino, Christopher M
Publicado 2023

Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection

por Boix, Vicente, Fedorak, Richard N., Mullane, Kathleen M., Pesant, Yves, Stoutenburgh, Uschi, Jin, Mandy, Adedoyin, Adedayo, Chesnel, Laurent, Guris, Dalya, Larson, Kajal B., Murata, Yoshihiko
Publicado 2017

Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneu...

por Caro, Luzelena, Nicolau, David P, De Waele, Jan J, Kuti, Joseph L, Larson, Kajal B, Gadzicki, Elaine, Yu, Brian, Zeng, Zhen, Adedoyin, Adedayo, Rhee, Elizabeth G
Publicado 2020

LB6. EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study

por Coakley, Eoin, Ahmad, Alaa, Larson, Kajal, McClure, Ty, Lin, Kai, Lin, Kai, Tenhoor, Kursten, Eze, Kingsley, Noulin, Nicolas, Horvathova, Veronika, Murray, Bryan, Baillet, Mark, Mori, Julie, Adda, Nathalie
Publicado 2019

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam...

por Bhavnani, Sujata M, Bhavnani, Sujata M, Bhavnani, Sujata M, Rubino, Christopher M, Hammel, Jeffrey P, Cammarata, Anthony P, Larson, Kajal, Liolios, Kathryn, McLeod, Sarah, Miller, Alita, Ambrose, Paul G, Tommasi, Ruben, O'Donnell, John
Publicado 2022